Corporate Magazine 2012 - Boehringer Ingelheim

positive development of new, innovative products in the2012 financial year allowed us to continue the period ofsustainable growth.We increased sales by 11.5% year-on-year to EUR 14,691million in 2012. The development of foreign exchangerates on the markets and the associated favourable exchangerate effects had a positive effect here (+ 5.2%),leading to a currency corrected growth of 6.3%.The Boehringer Ingelheim group’s activities are dividedinto the three business areas of Human Pharmaceuticals,Biopharmaceuticals and Animal Health. In turn, theHuman Pharmaceuticals business is subdivided into PrescriptionMedicines, Consumer Health Care and IndustrialCustomers. In 2012, our Human Pharmaceuticalsbusiness generated net sales of EUR 13,080 million, correspondingto sales growth of 12.0% compared with theprevious year (7.7% after adjustment for exchange rateeffects) and a share of around 89% in net sales.Prescription MedicinesWith a share of overall sales of around 78%, PrescriptionMedicines is the key pillar of our activities in the HumanPharmaceuticals business area. Net sales increased by13.0% to EUR 11,405 million in 2012 (7.1% after adjustmentfor exchange rate effects).Net sales (in millions of EUR) 2012 2011 Changespiriva® 3,562 3,153 13.0%micardis® 1,623 1,593 1.9%pradaxa® 1,108 629 76.2%combivent® 883 766 15.3%As in previous years, our highest-selling and most importantproduct was spiriva®, which is used to treat chronicobstructive pulmonary disease (COPD). In the reportingperiod, it generated revenues of over EUR 3,562 million,which equates to growth of around 13% compared with2011. In its largest sales market, the USA, sales increasedby a further 18.9% to EUR 1,789 million.Our second-largest product, micardis®, a drug for thetreatment of high blood pressure, also enjoyed positivedevelopment, with sales rising by around 1.9% to EUR1,623 million. Our new oral anticoagulant pradaxa® isthe fastest-growing product in our portfolio. In the reportingperiod, it generated revenues in excess of EUR1 billion for the first time (EUR 1,108 million), correspondingto year-on-year growth of 76.2%.Regional development of our Prescription Medicinesbusiness was varied. For the first time in two years, salesrose year-on-year in all regions, with the Americas andAsia/Australasia/Africa (AAA) regions posting strongdouble-digit growth, while Europe recorded a mid-single-digitincrease.In the Americas, Boehringer Ingelheim’s largest sales regionfor prescription medicines, sales amounted to EUR5,556 million in the past financial year (+15.0% comparedto previous year). This growth was driven in particularby the USA, which recorded the highest sales, with revenuesup 16.8% year-on-year to EUR 4,645 million.The AAA region achieved encouraging sales growth of18.3% to EUR 2,815 million. In Japan, the most importantAAA market for Boehringer Ingelheim, revenuesrose by 17.0% compared with 2011 to EUR 1,752 million.We expanded our business in the growing Chinesemarket by around 46.2% to sales of EUR 285 million.At EUR 2,822 million, sales in the Europe region wereup 5.7% on the previous year. Germany (+ 8.5%) and theUnited Kingdom (+ 9.3%), the most important countriesfor our Prescription Medicines business, posted encouragingincreases in revenue to EUR 578 million and EUR337 million respectively despite a challenging marketenvironment due to high cost pressure in the healthcaresystems. In the growth market of Russia, we increasedour revenues by 39.4% to EUR 188 million.32Boehringer Ingelheim annual report 2012